Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Intensity Therapeutics, Inc. ( (INTS) ) just unveiled an announcement.
On October 22, 2025, Intensity Therapeutics, Inc. held a special meeting of stockholders where approximately 46.61% of the outstanding shares were represented. The stockholders approved a proposal for a reverse stock split of the company’s common stock, with the exact ratio to be determined by the board of directors. Additionally, they approved the potential adjournment of the meeting to allow further solicitation if needed.
The most recent analyst rating on (INTS) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Intensity Therapeutics, Inc. stock, see the INTS Stock Forecast page.
Spark’s Take on INTS Stock
According to Spark, TipRanks’ AI Analyst, INTS is a Underperform.
Intensity Therapeutics faces significant challenges typical of a pre-revenue biotech firm, including negative financial metrics and bearish technical indicators. While recent corporate announcements about cancer treatment progress are promising, they do not outweigh the financial and technical difficulties. The overall score reflects these challenges, positioning the stock at the lower end of the scoring range.
To see Spark’s full report on INTS stock, click here.
More about Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of cancer immunotherapy products designed to enhance the immune system’s ability to fight cancer.
Average Trading Volume: 5,019,790
Technical Sentiment Signal: Sell
Current Market Cap: $12.55M
Learn more about INTS stock on TipRanks’ Stock Analysis page.